Astrocytoma, IDH-Mutant, Grade 3 Clinical Trials

6 clinical trials for Astrocytoma, IDH-Mutant, Grade 3 across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer — RECRUITING · PHASE3
• SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) — RECRUITING · PHASE3
• Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas — RECRUITING · PHASE1
• Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease — NOT_YET_RECRUITING · PHASE2
• Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma — ACTIVE_NOT_RECRUITING · PHASE1
• GliomaAI-Astro23: MRI-Based Detection of IDH Mutant Astrocytoma (Grade 2 and 3) — COMPLETED

Refine this search